Olympus Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

CEO

Olympus heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yasuo Takeuchi	Representative Executive Officer	12.6yrs	JP¥497.00m	0.022% ¥ 616.3m
Andre Roggan	Executive Officer & CTO	2.6yrs	JP¥462.00m	0.0022% ¥ 62.5m
Tetsuo Kobayashi	Executive Officer and Chief Manufacturing & Supply Officer	no data	JP¥119.00m	0.0036% ¥ 102.1m
Frank Drewalowski	Executive Officer & Endoscopic Solutions Division Head	4.8yrs	JP¥459.00m	0.0013% ¥ 36.0m
Gabriela Kaynor	Executive Officer & Chief Strategy Officer	no data	JP¥218.00m	0.00046% ¥ 12.9m
Tatsuya Izumi	Executive Officer & CFO	less than a year	geen gegevens	geen gegevens
Stephen Kneebone	Corporate Officer & Chief Information Officer	2.8yrs	JP¥734.00m	geen gegevens
Takaaki Sakurai	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Neil Tanner	Executive Officer & Global General Counsel	less than a year	geen gegevens	geen gegevens
Shigeto Ohtsuki	Executive Officer & Chief Human Resources Officer	4.8yrs	geen gegevens	0.00058% ¥ 16.3m
Hidenao Tsuchiya	Corporate Officer	no data	geen gegevens	geen gegevens
Georg Schloer	Head of Ear	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7733 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yasuo Takeuchi	Representative Executive Officer	12.6yrs	JP¥497.00m	0.022% ¥ 616.3m
Sumitaka Fujita	Independent Outside Director	12.6yrs	geen gegevens	0.0017% ¥ 49.0m
Jimmy C. Beasley	Independent Outside Director	5.4yrs	geen gegevens	0.00052% ¥ 14.6m
Gary John Pruden	Independent Outside Director	2.4yrs	geen gegevens	0.00040% ¥ 11.3m
Masato Iwasaki	Independent Outside Director	less than a year	geen gegevens	geen gegevens
David Robert Hale	Independent Outside Director	5.4yrs	geen gegevens	geen gegevens
Luann Marie Pendy	Independent Outside Director	1.4yrs	geen gegevens	0.00031% ¥ 8.7m
Toshihiko Okubo	Director	1.4yrs	geen gegevens	0.0022% ¥ 61.3m
Sachiko Ichikawa	Independent Outside Director	3.4yrs	geen gegevens	0.00063% ¥ 17.7m
Kohei Kan	Independent Outside Director	2.4yrs	geen gegevens	0.00065% ¥ 18.3m

2.9yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7733 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

Olympus Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation Announces Executive Changes

Recent updates

Olympus' (TSE:7733) Strong Earnings Are Of Good Quality

Dividend of JP¥20.00 announced

Second quarter 2025 earnings: EPS misses analyst expectations

Olympus Corporation's (TSE:7733) Share Price Could Signal Some Risk

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus (TSE:7733) Hasn't Managed To Accelerate Its Returns

A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Estimating The Fair Value Of Olympus Corporation (TSE:7733)

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Slowing Rates Of Return At Olympus (TSE:7733) Leave Little Room For Excitement

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Upcoming dividend of JP¥18.00 per share

Olympus Corporation's (TSE:7733) Share Price Matching Investor Opinion

Dividend of JP¥18.00 announced

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

New minor risk - Earnings quality

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Now 21% overvalued after recent price rise

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS misses analyst expectations

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 38%

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Now 21% undervalued after recent price drop

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Now 21% undervalued

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Upcoming dividend of JP¥16.00 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: JP¥28.43 (vs JP¥19.66 in 3Q 2022)

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released

Second quarter 2023 earnings released

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Full year 2022 earnings: Revenues in line with analyst expectations

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Investor sentiment improved over the past week

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023